Abstract | OBJECTIVE: METHOD: 19 patients were treated with the following protocol: Nimotuzumab 400mg/time/week in the 1(st) week, 200mg/time/week from the 2(nd) to 8(th) week, intravenous drip (IVD); Cisplatin 80 mg/m(2), IVD, 4 weeks a cycle and repeated again; 5-FU 750 mg/m(2), continuous 24-hours pump-in × 5 days, 4 weeks a cycle and repeated again. RESULT: 16 of all 19 patients can be evaluated. After treatment, RP is 42.1% (95% CI, 19.9-64.3%) and DCR is 68.4%; the main side effects include arrest of bone marrow, gastrointestinal reactions, asthenia, etc. CONCLUSION:
Nimotuzumab in combination with cisplatin/5-FU regimens in patients with advanced ESCC is safe and effective, which deserves a further expanded sample research.
|
Authors | Yang Ling, Jia Chen, Min Tao, Xiaoyuan Chu, Xizhi Zhang |
Journal | Journal of thoracic disease
(J Thorac Dis)
Vol. 4
Issue 1
Pg. 58-62
(Feb 2012)
ISSN: 2077-6624 [Electronic] China |
PMID | 22295168
(Publication Type: Journal Article)
|